111 Capital Purchases Shares of 1,576 Amgen Inc. (NASDAQ:AMGN)

111 Capital bought a new position in Amgen Inc. (NASDAQ:AMGN - Free Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 1,576 shares of the medical research company's stock, valued at approximately $411,000.

Other institutional investors have also recently made changes to their positions in the company. Ascent Wealth Partners LLC grew its stake in shares of Amgen by 0.7% in the 4th quarter. Ascent Wealth Partners LLC now owns 9,024 shares of the medical research company's stock worth $2,352,000 after acquiring an additional 64 shares in the last quarter. ICICI Prudential Asset Management Co Ltd grew its position in Amgen by 242.2% during the fourth quarter. ICICI Prudential Asset Management Co Ltd now owns 23,999 shares of the medical research company's stock valued at $6,255,000 after buying an additional 16,985 shares during the period. Fisher Asset Management LLC grew its position in Amgen by 285.4% during the fourth quarter. Fisher Asset Management LLC now owns 394,489 shares of the medical research company's stock valued at $102,820,000 after buying an additional 292,137 shares during the period. Aire Advisors LLC grew its position in Amgen by 26.3% during the fourth quarter. Aire Advisors LLC now owns 13,280 shares of the medical research company's stock valued at $3,461,000 after buying an additional 2,762 shares during the period. Finally, Beacon Harbor Wealth Advisors Inc. bought a new position in Amgen during the fourth quarter valued at about $3,531,000. Institutional investors own 76.50% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the stock. Piper Sandler reduced their price target on shares of Amgen from $329.00 to $328.00 and set an "overweight" rating for the company in a research report on Friday, May 16th. UBS Group restated a "neutral" rating and set a $315.00 price target (down previously from $319.00) on shares of Amgen in a research report on Friday, May 2nd. Mizuho increased their price target on shares of Amgen from $235.00 to $280.00 and gave the company a "neutral" rating in a research report on Wednesday, May 7th. Royal Bank of Canada reduced their price target on shares of Amgen from $324.00 to $320.00 and set an "outperform" rating for the company in a research report on Friday, May 2nd. Finally, Citigroup restated a "neutral" rating on shares of Amgen in a research report on Wednesday, February 5th. Two equities research analysts have rated the stock with a sell rating, twelve have issued a hold rating, nine have issued a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and an average target price of $309.22.

Amgen Price Performance

Shares of Amgen stock traded up $3.48 on Friday, reaching $287.02. The stock had a trading volume of 5,437,576 shares, compared to its average volume of 2,806,757. Amgen Inc. has a 1 year low of $253.30 and a 1 year high of $346.85. The company has a market cap of $154.33 billion, a P/E ratio of 38.02, a price-to-earnings-growth ratio of 2.63 and a beta of 0.51. The company has a current ratio of 1.26, a quick ratio of 0.95 and a debt-to-equity ratio of 9.62. The business's 50 day moving average is $283.46 and its two-hundred day moving average is $285.31.

Amgen (NASDAQ:AMGN - Get Free Report) last announced its earnings results on Thursday, May 1st. The medical research company reported $4.90 earnings per share for the quarter, beating analysts' consensus estimates of $4.18 by $0.72. The business had revenue of $8.15 billion for the quarter, compared to the consensus estimate of $8.05 billion. Amgen had a net margin of 12.24% and a return on equity of 176.32%. Amgen's quarterly revenue was up 9.4% on a year-over-year basis. During the same period last year, the firm posted $3.96 earnings per share. As a group, research analysts anticipate that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Friday, May 16th will be paid a $2.38 dividend. This represents a $9.52 dividend on an annualized basis and a yield of 3.32%. The ex-dividend date is Friday, May 16th. Amgen's dividend payout ratio is currently 86.86%.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.